Maternal vitamin D supplementation during pregnancy and lactation to promote infant growth in Dhaka, Bangladesh (MDIG trial): study protocol for a randomized controlled trial

Table 1 Vitamin D₃ and excipient content of custom-made tablets for the Maternal Vitamin D for Infant Growth trial^a

Content type	Tablet contents
Granules^b	Vitamin D₃^c
	α-Tocopherol^d
	Corn starch
	Medium-chain triglycerides
	Acacia gum
	Sucrose
	Dibasic calcium phosphate
Additional tablet excipients	Croscarmellose sodium
Additional tablet excipients	Silicon dioxide
Tablet coating	Hydroxypropylmethylcellulose
	Polyethylene glycol 6000
	Titanium dioxide

^aComposition information provided by the manufacturer (Toronto Institute of Pharmaceutical Technology, Toronto, ON, Canada)
^bPlacebo granules were identical except for the absence of vitamin D₃
^cDry vitamin D₃ 100 GFP/HP (BASF, Mississauga, ON, Canada)
^dα-Tocopherol is included as an antioxidant to stabilize the vitamin D₃. The vitamin E content of each tablet is 2.8 mg/wk (about 0.4 mg/day), which is far below recommended dietary allowances for pregnancy (15 mg/day) and lactation (19 mg/day)

ISSN: 1745-6215